2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 1,001–1,100 of 2,029
Puig, R., Rodríguez‐Peña, M., Hernández-Montoliu, L., Astiarraga, B., Martínez, E., Balibrea, J. M., Llauradó, G., Tarascó, J., Boza, A. C., Joaquín, C., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-025-01971-7 · Cited by 2
Shareef, I., Akbar, U., Usmani, M., et al. (2026) · Cureus · doi:10.7759/cureus.101239 · Cited by 1
Lefaucheur, J., Gendre, T., & Sène, D. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1679316 · Cited by 1
Soepnel, L. M., Conradie, C. M., Geffen, H., Choo-Kang, C., Bovet, P., Viswanathan, B., Bedu-Addo, K., Boateng, P. O., Dei, O. A., Apusiga, K., et al. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003427 · Cited by 2
“This cut-off was chosen in line with the American Diabetes Association definition of impaired glucose tolerance, 27 rather than the fasting glucose criteria of ≥ 7 mmol/L (126 mg/dL), to allow for a consistent definition between the sites and to prevent over-estimation of high blood glucose due to…”
Hong, H.-S., Zhu, D.-Q., Kang, L.-H., Zhou, Y.-M., & Ke, R.-Q. (2026) · European journal of medical research · doi:10.1186/s40001-026-03884-1 · Cited by 1
Wang, S., Liu, Z., Feng, N., Guo, Y., Chen, Q., Cao, Y., Li, X., Liu, X. G., & Yan, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1748335 · Cited by 1
Jin, X., Chen, X., Chen, H., & Hong, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021070 · Cited by 2
“Blood glucose testing remains the primary diagnostic tool [5]; however, it only reflects abnormalities in glucose metabolism on a superficial level and cannot directly address the underlying metabolic dysregulations that drive these outcomes.”
Wang, Y., Dong, C., Feng, Y., Zhang, W., Yuan, M., Ma, Y., Liu, C., & Gao, D. (2026) · European journal of medical research · doi:10.1186/s40001-026-03909-9 · Cited by 2
“Concur-rently, baseline clinical data were systematically collected, including RDW, demographic characteristics (age and sex), vital signs (SBP and heart rate), comorbidities (such as hypertension [22] and diabetes[20]), smoking status, and a panel of biochemical laboratory parameters.”
InfluentialDrucker, G., Mayfield, C., Steeves, E. A., Maksi, S. J., Underwood, T., Brown, J. A., Frick, M., & Gustafson, A. (2026) · Nutrients · doi:10.3390/nu18020354 · Cited by 1
“A1c: Hemoglobin A1c (normal HbA1c 5.7% for both children and adults [34]).”
InfluentialAkhtar, R., Rathi, D., Khalid, M., Jairamani, S., Amir, A., Ali, U., Siraj, A., Abbasi, M., Kumari, U., Waqas, S., et al. (2026) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702251408828 · Cited by 2
Tian, Z., Ren, X., Wang, Q., Guo, W., Li, H., & Shang, L. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1762971 · Cited by 1
Chandra, K. P., GUPTA, M., Awasthi, R., Pande, A. R., Gupta, N., Kumar, D., Agarwal, V., Gupta, T., AWASTHI, S., & Lachhwani, H. (2026) · Cureus · doi:10.7759/cureus.102866 · Cited by 2
Wang, Y., Feng, L., Wang, Y., Li, B., Liang, N., Song, X., Qin, J., Zhang, M., & Li, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2620155 · Cited by 2
“…cKD populations. the FLOw trial successfully addressed this gap by evaluating GLP-1Ras in patients with cKD and t2Dm, and both the KDiGO 2024 and aDa 2025 guidelines have newly incorporated recommendations for GLP-1Ras in patients with cKD and t2Dm who have not achieved glycemic targets [33,46,47].”
Alemu, L. S., Chopra, K., & Jain, R. K. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag025
“We defined DM by hemoglobin A1c of 6.5% or greater [9].”
InfluentialMurtaza, M., Shahid, H., Khanzada, M. B., et al. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100304 · Cited by 1
Lizarzaburu-Robles, J. C., Herman, W. H., Garro-Mendiola, A., Mahillo-Fernández, I., Lazo-Porras, M., Mas, S., Paniagua, A., Vázquez-Martínez, C., Vento, F., Valera, J., et al. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag029 · Cited by 1
Chen, J., Zhang, X., Liu, K., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1726502 · Cited by 1
Balcı, M. F., Akdemir, C., Yıldırım, F., Karaca, S. Y., & Karaca, I. O. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02192-3 · Cited by 2
“It exerts significant short-and long-term effects on both maternal and fetal health, increasing the risk of preeclampsia, macrosomia, cesarean delivery, and congenital metabolic disorders [1].”
Prengemann, L., Stein, R., Gausche, R., Beger, C., Vogel, M., Wenzel, E., Stoltze, A., Kiess, W., Pfäffle, R. W., & Körner, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf672 · Cited by 2
Milushewa, P., Chenesheva, N., & Petkova, V. B. (2026) · Pharmacy · doi:10.3390/pharmacy14010035 · Cited by 1
“The predominance of oral antidiabetic therapy and the widespread use of metformin observed in this study are consistent with current international recommendations, which continue to position metformin as first-line therapy in patients without contraindications or high cardiovascular risk [13,14].”
Zhang, R., Chen, X., Zhou, B., Xiang, B., & Zhu, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1718936 · Cited by 3
Nemati, S., Saberi, A., Reyhani, Y., Khanhakimi, M., Hosseinpour, N., & Nasirmohtaram, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-40363-3 · Cited by 2
Montemayor, M. T., Ackerer, A. D., Lacroix, A., Collet, T., Dizès, O. L., Quansah, D. Y., & Puder, J. J. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109293 · Cited by 1
Squirrell, D., Nielsen, C., Vaghefi, E., An, S., Moghadam, S., Yang, S., Xie, L., Rahimi, A., Durbin, M. K., Hou, H., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-41465-8 · Cited by 3
“Diabetes was defined as HbA1c ≥ 6.5% 38 .”
InfluentialBartáková, V., Ambrožová, E., Žák, P., & Kaňková, K. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1778006 · Cited by 2
Saez-Berlanga, Á., Gené‐Morales, J., Babiloni-López, C., Jiménez‐Martínez, P., Juesas, Á., & Colado, J. C. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.02.485 · Cited by 2
Ma, R., Ma, Y., li, X., Ding, K., Xiao, H., Liu, Y., Chen, D., & Cao, W. (2026) · Biomedicines · doi:10.3390/biomedicines14030568 · Cited by 1
“…the following criteria were met: glycated hemoglobin (HbA1c) > 6.5%; fasting blood glucose ≥ 7.0 mmol/L; random blood glucose ≥ 11.1 mmol/L; 2 h blood glucose ≥ 11.1 mmol/L in the oral glucose tolerance test (OGTT); self-reported doctor-diagnosed history; or current use of hypoglycemic drugs [27].”
InfluentialYohanes, D., & Chowanda, A. (2025) · International Conference of Science and Information Technology in Smart Administration (ICSINTESA) · doi:10.1109/icsintesa68165.2025.11413621 · Cited by 1
Effects of Carvacrol on Aortic Damage in a Streptozotocin-Induced Type 1 Diabetic Rat Model
Karabekir, S. C., Gültekin, B., Savaş, H. B., Cüce, G., & Kalkan, S. S. (2026) · Biomolecules · doi:10.3390/biom16030431 · Cited by 1
“Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder that typically begins in childhood or adolescence and accounts for approximately 10% of all diabetes cases [1].”
Saluja, K. V., Balachandran, P., Pillai, D., Meena, D., Saxena, S., Khokhar, H., Khandelwal, G., Manoj, S., Chittora, S., & Bhadra, P. (2026) · Scientific Reports · doi:10.1038/s41598-026-44608-z · Cited by 1
“In this study, the American Diabetes Association (ADA) criterion for fasting blood glucose (FBG) was used to diagnose T2DM incidence in patients, as FBG is recognized as a reliable diagnostic marker ensuring consistency across clinical and research settings 71 .”
Evaluation and management of metabolic-associated chronic kidney disease
Bavanandan, S., & Prasad, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102098 · Cited by 1
Yin, S., Zhong, L., Gao, L., Shao, Q., Wang, L., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1786731 · Cited by 1
“The diagnosis of normal glucose tolerance (NGT), prediabetes (Pre-DM), and diabetes followed the criteria set by the American Diabetes Association in 2024 (24).”
Lee, H. J., Doolittle, W. K. L., & Lee, K. T. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04733-5 · Cited by 1
“For T3cDM, the diagnosis and classification of diabetes by American Diabetes Association (ADA) recommend screening people for diabetes within 3–6 months following an episode of acute pancreatitis and annually patients with chronic pancreatitis [26].”
Taschereau, A., Wong, J., Harnois‐Leblanc, S., Brunet, M. A., Doyon, M., Arguin, M., Rifas‐Shiman, S. L., Oken, E., Perron, P., Jacques, P., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s590000 · Cited by 2
Veterans Hospitals vs Non-Veterans Centers in the Prevention of Limb Loss
Ponukumati, A. S., Columbo, J. A., Joseph, R., Berceli, S. A., Goodney, P. P., Davies, L., Soybel, D. I., Scali, S. T., & Stone, D. H. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.0489 · Cited by 2
Zhang, B., Dong, Y., Li, Y., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05755-3 · Cited by 1
“Diabetes mellitus was defined as fasting plasma glucose ≥ 7.0 mmol/L and/or glycated hemoglobin (HbA1c) ≥ 6.5%, or current glucose-lowering therapy [19].”
InfluentialClinical application of fecal microbiota transplantation and its influencing factors
Wang, B., Deng, F., Liu, Z., Tian, J., Li, Y., Mao, Y., & Song, H. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1807071 · Cited by 2
Wang, H., Xiang, Y., Chen, L. L., et al. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-03975-4 · Cited by 1
“…management of elevated blood pressure and hypertension [11]), diabetes mellitus (diagnosed per the 2024 ADA Standards of Medical Care in Diabetes [12]), current smoking status, obesity (body mass index [BMI] ≥ 28 kg/m²), dyslipidemia (defined by the 2023 Chinese Guidelines for Lipid Management…”
Pan, W., Liao, Y., Han, Y., Cao, C., & Hu, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1713333 · Cited by 2
Ding, J., Qu, C., Yan, Y., Ma, J., & Na, L. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag015 · Cited by 1
Kwak, K., Jung, S., Kwon, D., & Lee, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072797 · Cited by 1
“[25].”
Sivakumar, R., Aravaanan, A. S. K., Mohanakrishnan, V. V., & Kumar, J. (2026) · Diseases · doi:10.3390/diseases14040140 · Cited by 2
“%) for subgroup analysis [25,26].”
InfluentialFelício, J. S., Chambouleyron, E., Nascimento, V., Fernandes, I. J., Ruivo, L. O., Hupp, M. V. S., Silva, L., de Queiroz, N. N. M., de Melo, F. T. C., de Souza, A. C., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1810159 · Cited by 1
Prayitnaningsih, S., Syarifuddin, O., Dhani, F. K., Novita, H. D., Samsu, N., Sasongko, M. B., Dewi, C., & Yudistira, N. (2026) · Clinical ophthalmology · doi:10.2147/opth.s586474 · Cited by 3
The First Selective Screening for Type 1 Diabetes in a Pediatric Population in Bulgaria
Yaneva, N., Petrova, M., Yordanova, A., Popov, T. T., Arshinkova, M., Kyurkchiev, D., & Kurteva, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083075 · Cited by 1
“Clinical stages of T1D were diagnosed according to the standardized criteria of the American Diabetes Association (ADA) [26].”
RNA Modifications: Current Understandings and Future Perspectives
Xiao, S., Xiang, T., Yang, C., Wang, X., Huang, G., Luo, F., Xie, Z., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70734 · Cited by 4
Effect of RYGB Limb Lengths on HbA1c in Patients with Obesity and Type 2 Diabetes
Seidemann, L., Morgenroth, R., Moulla, Y., Lange, U. G., Lyros, O., Blüher, M., Petroff, D., Prettin, C., Köhler, N., & Dietrich, A. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08690-6 · Cited by 2
“Furthermore, 5.7% represents the lower boundary of prediabetes according to the American Diabetes Association (ADA) [16], meaning that the average long BPL-RYGB patient achieved not only diabetes remission but near-normal HbA1c levels.”
InfluentialComplete Blood Count-Derived Inflammatory Indices in Prediabetes: A Head-to-Head Comparison
Lule, K. O., Özsoy, Ö., YILDIRIM, O., & Yıldız, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083160 · Cited by 1
“Prediabetes was defined according to the American Diabetes Association criteria [1] as fasting plasma glucose levels of 100–125 mg/dL and/or glycated hemoglobin (HbA1c) levels of 5.7–6.4%.”
InfluentialYuan, Q., He, S., Elhassan, M. A. M., Yu, C., Lu, J., Fang, L., Zhu, X., Wu, Z., He, J., & Gu, W. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121830 · Cited by 1
Ji, S., Shang, F., Chen, B., Tang, W., Fang, H., Huang, J., & Hu, Y. (2026) · International Journal of Endocrinology · doi:10.1155/ije/8881466 · Cited by 2
Vega-Fleitas, E., & Moll-López, S. (2026) · RSC Advances · doi:10.1039/d6ra01076h · Cited by 1
Li, X., Meng, Y., Zhang, L., Li, T., & Yan, G. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03181-5 · Cited by 2
“Glycemic status represents a spectrum from normal glucose tolerance (NGT) through prediabetes to overt type 2 diabetes (T2D), each stage characterized by progressively worsening IR, inflammation, and metabolic dysregulation [19].”
Thakur, S., Munshi, A., & Kaur, P. (2026) · Molecular Biotechnology · doi:10.1007/s12033-026-01576-z · Cited by 3
Ifeanyichi, M., Gómez-Pérez, G. P., Banigbe, B., Dada, I., Dada, A. A., Zamba, E., van Andel, J. M., de Wit, T. F. R., & Dieteren, C. (2026) · BMJ Global Health · doi:10.1136/bmjgh-2025-019477 · Cited by 1
“32 We excluded patients with documented macrovascular or microvascular complications to ensure that the cost and benefit estimates reflected optimisation of uncomplicated type 2 diabetes management pathways.”
Xerfan, E. M. S., Souza, M. R., Araujo, P., Tufik, S. E. R., & Andersen, M. L. (2026) · HORMONES · doi:10.1007/s42000-025-00751-2 · Cited by 1
“…antihypertensive medication) [20 ]; diabetes (fasting glucose ≥ 126 mg/dL, glycated hemoglobin [HbA1c] ≥ 6.5%, or use of antidiabetic medication) [21 ]; dyslipidemia (high-density lipoprotein [HDL] cholesterol < 40 mg/dL in men, < 50 mg/dL in women, triglycerides ≥ 150 mg/dL, or use of…”
InfluentialWu, M., Yao, H., Zhao, D., et al. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120249 · Cited by 1
Bagheri‐Hosseinabadi, Z., Naiini, M. R., Mohammadi, N. M., Abbasifard, M., Arami, F., Shahouzehi, B., Mohammadi-Hosseinabad, S., & Mirzaei, M. R. (2026) · Scientific Reports · doi:10.1038/s41598-026-51968-z · Cited by 3
“T2DM was defined as a fasting blood sugar (FBS) ≥ 126 mg/dL or a self-reported physician diagnosis accompanied by the use of anti-diabetic medication 25 .”
Screening Programs for Type 1 Diabetes in Youth: Evidence for Clinical Practice
Franceschi, R., Mozzillo, E., Marigliano, M., Maltoni, G., Maddaloni, E., Amendolara, R., Bernardini, L., Bonfanti, R., Ciambrelli, F., Candia, F. D., et al. (2026) · PEDIATRICS · doi:10.1542/peds.2025-075728 · Cited by 1
Xu, X., Yang, R., Zhou, Q., Han, S., Guo, M., Shan, X., Han, T., Jiang, W., & Fan, S. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100006 · Cited by 1
John, J. P., Varghese, A., Varghese, S., & Philip, T. (2026) · Cureus · doi:10.7759/cureus.109570 · Cited by 2
Secondulfo, C., Russo, D., Vecchione, N., Minelli, G., Apicella, L., Iacuzzo, C., Crescenzo, C., Minco, M., Sannino, A., Clemente, G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114832 · Cited by 1
Stoian, A., Cernea, S., BÄnescu, C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114995 · Cited by 1
“…mellitus was confirmed by a diabetologist according to the American Diabetes Association guidelines: fasting plasma glucose ≥ 126 mg/dL, 2 h plasma glucose ≥ 200 mg/dL during a 75 g oral glucose tolerance test, glycosylated hemoglobin (HbA1c) ≥ 6.5%, or random plasma glucose ≥ 200 mg/dL [71].”
Influential郭灵丹, Li, J., Jia, L., Chen, S., Li, M., Yang, J., Xiao, L., Shen, J., & Liu, J. (2026) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2026.1781403 · Cited by 1
“Gestational diabetes mellitus was diagnosed according to the American Diabetes Association (2021) criteria, defined as fasting blood glucose ≥ 92 mg/dL or 2-hour blood glucose ≥ 153 mg/dL during a 75-g oral glucose tolerance test (20, 21).”
Heo, J. H., Sung, D.-E., Kang, J., Zhou, X., Zheng, M., & Sung, K. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104817 · Cited by 1
GO MOMs Study Group*, Scholtens, D., Siddique, J., Bustamante, P., Cheung, Y., Grott, T., Kuang, A., Banker, M. M., Tull, M. B., & Guachichullca, J. (2026) · Diabetes Care · doi:10.2337/dc26-0302 · Cited by 6
Cao, H.-Y., Mo, Z.-W., Ma, Z.-S., Liu, Y.-F., Wang, C., Peng, Y.-M., Kang, Y.-T., Li, Y., Ou, Z., & Ou, J. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3308-1 · Cited by 2
Multiple Correspondence Analysis reveals two different phenotypes of idiopathic chronic pancreatitis
Guilabert, L., Maisonneuve, P., Deli, C., Bellafante, D., Apadula, L., Marengon, I., Vanella, G., Tacelli, M., Dell’Anna, G., Petrone, M. C., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.05.012 · Cited by 2
Sarić, M. M., Šikić, N. L., Sorić, T., Sarić, A., Ivanišin, A., Brodić, I., & Milić, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125495 · Cited by 2
“The American Diabetes Association notes that HbA1c may fail to identify a substantial proportion of individuals with impaired fasting glucose, supporting the use of complementary biomarkers in early assessment [43].”
Tol, M. C., de Vos, W., Alwayn, I. P. J., Mieog, J. S. D., van Hooft, J. E., Inderson, A., Niesters, M., Hellinga, M. D., Nijhoff, M. F., van Erkel, A. R., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06772-9 · Cited by 1
“%) or fasting glucose ≥7 mmol/l [31], or requiring glucose-lowering therapy.”
Oraebosi, M. I., Baucom, C., & Cao, R. (2026) · Diabetology · doi:10.3390/diabetology7070122 · Cited by 2
“Clinically, patients are diagnosed with diabetes mellitus by fasting blood glucose (FBG) of ≥ 7.0 mmol/L (126 mg/dL); random blood glucose (RBG) ≥ 11.1 mmol/L (200 mg/dL) or blood glucose ≥ 11.1 mmol/L (200 mg/dL) 2 h after oral glucose tolerance test (OGTT) [1].”
InfluentialYang, Y., Qu, X., Shi, M., Huang, J., Li, G. X., Lu, X., You, E., Qian, J., Xu, J., Jiang, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03272-3 · Cited by 2
“In the NAGALA cohort, T2DM status was determined according to the diabetes diagnosis and glucose-and HbA1c-related variables available in the original dataset [20].”
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
Krishna, S., Dungan, K. M., Shah, R., Cruz‐Monserrate, Z., DelGiorno, K. E., Tan, M., & Hart, P. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00069-9 · Cited by 1
“When combined with the exclusion of patients with either acute or chronic pancreatitis from prior clinical trials, this observation aligns with the caution raised by the American Diabetes Association to avoid use of GLP-1RAs for patients with any history of acute or chronic pancreatitis 27 .”
Li, Y., Song, W., Huan, C., Xu, K., Sun, J., Zhen, X., Ouyang, H., Tang, H., Fan, Q., Zhi, W., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109089 · Cited by 3
Thiazolidinedione nucleus: a molecular beacon in treatment of diabetes
Mehra, A., Mittal, A., & Singh, S. (2026) · Journal of Sulfur Chemistry · doi:10.1080/17415993.2026.2709110 · Cited by 1
“Existing management approaches involve lifestyle change and pharmacological management that are based on enhancing glycemic control and sensitivity to insulin [5,6].”
Chen, Y., He, F., Zhang, L., & Zhang, Z. (2026) · Adipocyte · doi:10.1080/21623945.2026.2705620 · Cited by 1
“Currently, the clinical diagnosis of GDM primarily relies on oral glucose tolerance test (OGTT) performed during the second trimester of pregnancy [5,6].”
Kim, E., Ko, N. G., & Jin, M. (2026) · Ophthalmic Epidemiology · doi:10.1080/09286586.2026.2713597 · Cited by 1
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
“For patients living with T2D who also have heart failure (HF) and CKD, selected therapies such as SGLT2i and/or GLP-1 RA are preferred based on evidence that they reduce CV and kidney disease risk [28].”
Lekić, I., Marczi, S., Stević, M. S., Nešković, N., Tokić, S., Marušić, R., Bugarin, A., Petřek, M., & Bačun, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1928474 · Cited by 1
Wong, H. J., Au, J. X. Y., Teo, Y. H., Teo, Y. N., Low, C. E., Yau, C. E., Lin, N. H. Y., Eng, P. C., Tan, L. F., Merchant, R. A., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70429 · Cited by 1
“We included all fi rst-onset STEMI cases reported to SMIR from January 2008 to December 2020 occurring in patients without DM. Non-DM was de fi ned as the absence of a prior diagnosis of DM and a presenting HbA1c of 6.5% 15 .”
InfluentialHuang, R., Huang, M., & Zhang, R. (2026) · British Journal Of Nutrition · doi:10.1017/s0007114526108332 · Cited by 1
Kazé, A. D., Ani, C., Fox, E. R., Hall, M. E., Yeneneh, B. T., Mentz, R. J., Bertoni, A. G., & Echouffo-Tcheugui, J. B. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048360 · Cited by 1
Demissie, G. D., Birungi, J., Haregu, T., Sathish, T., & Oldenburg, B. F. (2024) · JMIR Research Protocols · doi:10.2196/53517 · Cited by 1
“High diabetes risk scores: for example, the Indian Diabetes Risk Score ≥ 60 [31], the Finnish Diabetes Risk Score ≥ 12 [32], the ADA risk test ≥ 5 points [33],”
BackgroundInfluence of Blood Glycemia Levels in Refraction, Binocular Vision and Accommodation: A Case Report
Argilés, M., Sala-Oller, J., Sunyer-Grau, B., et al. (2024) · Reports — Medical Cases Images and Videos · doi:10.3390/reports7020022 · Cited by 1
“Insulin is a hormone produced and secreted in the pancreas by beta-cells, and its function is to regulate blood sugar levels by allowing glucose to enter the cells [1].”
BackgroundTalanki, A. S., Bajaj, N., Trehan, T., & Sathish, T. (2024) · JMIR Research Protocols · doi:10.2196/54853 · Cited by 2
“Prediabetes is defined as FPG 100 or 110 to 125 mg/dL, 2-h PG 140 to 199 mg/dL, RBG 140 to 199 mg/dL, HbA 1c 5.7% or 6.0% to 6.4% [26,27], or diagnosed using ICD-10 codes or similar codes [25].”
MethodInfluentialLee, H. S., Lim, H. I., Moon, T. J., Lee, S., & Lee, J. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03583-1 · Cited by 1
Zarei, S., & Soveid, M. (2024) · Shiraz E-Medical Journal · doi:10.5812/semj-142064 · Cited by 3
Ayat, P., Sawassnajjar, D., Alkaissi, H. R., Gill, H., Otey, J., AlFaraj, M., & McFarlane, S. I. (2024) · Cureus · doi:10.7759/cureus.63061 · Cited by 1
“Prediabetes is defined as glycated hemoglobin (HbA1c) ranging between 5.7% and 6.4%, fasting plasma glucose ranging between 100 and 125 mg/dL, or two-hour plasma glucose after a 75-g oral glucose tolerance test ranging between 140 and 199 mg/dL, and higher values are used to diagnose diabetes [9].”
BackgroundInfluentialAlgethami, A. M., Alfahmi, F. K., Alhusayni, M. A., Bamusa, S. A., Alsalmi, Y. I., Alboqami, A. F., & Aldosari, A. F. (2024) · Cureus · doi:10.7759/cureus.64124 · Cited by 3
Campos, M. A., Oppermann, M. L. D. R., Sanseverino, M. T. V., GUERRA, G. L., Hirakata, V. N., & Reichelt, A. J. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01376-y · Cited by 2
Nascimento, T., Espírito‐Santo, M., Gonçalves, A., Pinto, E. A. M., Sousa‐Coelho, A. L. D., & Estêvão, M. D. (2024) · Diabetology · doi:10.3390/diabetology5030024 · Cited by 2
“Persistent insulin resistance often leads to the development of type 2 diabetes mellitus (T2DM), a metabolic disease characterized by chronic hyperglycaemia, due to an impaired capacity of glucose utilization as an energy source, along with impaired gluconeogenesis and glycogenolysis [2,3].”
BackgroundMethodPeriodontitis and diabetes in pregnant rats: Maternal-fetal outcomes
Souza, S. S., da Cruz, L. L., Alves-Reis, A. M., Costa, V. Q., Moraes-Souza, R. Q., Damasceno, D. C., & Volpato, G. T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37394 · Cited by 1
Rathod, L., Khan, S., Shubham, S., Bisne, N., Singh, S., Kumar, M., Tiwari, R., & Sarma, D. K. (2024) · Cureus · doi:10.7759/cureus.69956 · Cited by 1
Nolasco-Rosales, G. A., Martínez‐Magaña, J. J., Juárez-Rojop, I. E., Rodríguez-Sánchez, E., Ruíz-Ramos, D., Velázquez, J. A. V., Bustos-Gamiño, M. N., Medina‐Mora, M. E., Tovilla‐Zárate, C. A., Cruz-Castillo, J. D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810154 · Cited by 1
“LADA is characterized by slower autoimmune destruction of the β -cells compared to T1D, where glutamate decarboxylase autoantibodies (GADA) are the predominant serum marker [3,4].”
BackgroundSwaby, R., Scudder, C. L., Randell, T. L., Marcovecchio, M. L., Gillespie, K. M., Liu, Y., Todd, J. A., Dunseath, G. J., Luzio, S. D., Dayan, C. M., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.23028.1 · Cited by 2
Bergmann, K., Stefańska, A., Kubica, J., Krintus, M., & Panteghini, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237126 · Cited by 2
“[ 17].”
Швед, М. І., Yastremska, I. O., Levytska, L. V., et al. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.7.2024.1449 · Cited by 1
Glycated hemoglobin and microalbuminuria in patients with type 2 diabetes mellitus
Zeqiraj, A., Zeqiraj, D., MullaGoga, T., Krasniqi, F., Shabani, A., Berisha, S., Berisha, A., Morina, B., & Zogaj, F. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.7.2024.1448 · Cited by 1
Antelo-Pais, P., Prieto-Díaz, M. Á., Micó-Pérez, R. M., et al. (2024) · Biomolecules · doi:10.3390/biom14121530 · Cited by 1
“On the one hand, there were differences described in terms of CVRFs [24]; and on the other, there were also differences in the prevalence of AMI [25].”
Screening fasting glucose before the OGTT: near-patient glucometer- or laboratory-based measurement?
Lippi, G., Ferrari, A. M., Visconti, S., et al. (2024) · Diagnosis · doi:10.1515/dx-2024-0176 · Cited by 1
Mohamed, A. S., Ahmad, H. M., Sharawy, M. A., & Kamel, F. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00818-7 · Cited by 3
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.